Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

82958bfc7df1311fd17a008495fc-1456375

Pharma in 2018: Looking back, looking forward

December 18, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, Alligator Bioscience, Eisai, Gilead, Mundipharma, pharma

2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 …

Feature
pharmafocus_dec_2018_cover

The December issue of Pharmafocus is available to read online now!

December 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eisai, GSK, Gilead, Mundipharma, Pharmafocus, mesothelioma, pharma

The December edition of Pharmafocus is live and available to read online now!Brexit continues to dominate the headlines inside and …

News

Gilead names Roche veteran Daniel O’Day as new CEO

December 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Gilead, Roche, appointment

Almost half a year since it was revealed that Gilead’s Dr John Milligan would be stepping down from his role …

News
gilead-sciences

NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma

December 7, 2018
Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access

The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …

News
gilead-sciences

Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

December 3, 2018
Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …

News
gilead_hq_at_stockley_park_london_2

NHS England appoves Gilead’s CAR T therapy Yescarta

October 5, 2018
Medical Communications Gilead, NHS, NICE, UK, Yescarta

Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive …

News
gilead-sciences

Gilead to release generic versions of hep C meds over a decade before patent expiry

September 28, 2018
Medical Communications, Sales and Marketing Epclusa, Gilead, generics, harvoni, hepatitis C, pharma

Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of …

News
gilead-sciences

Gilead and Galapagos’ ankylosing spondylitis drug hits Phase 2 trial goal

September 7, 2018
Medical Communications, Research and Development Galapagos, Gilead, ankylosing spondylitis, filgotinib, pharma

Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase …

News

Novartis’ CAR T therapy Kymriah to become available on the NHS

September 5, 2018
Research and Development CAR T, CAR-T, Gilead, Kymriah, NHS, Novartis

Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …

News
european_commission_web

Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies

August 28, 2018
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

News
andrew_cheng

Gilead CMO announces departure alongside two new exec appointments

August 17, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma

Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the …

Appointment
gilead-sciences

Gilead CMO announces departure alongside two new exec appointments

August 15, 2018
Medical Communications, Research and Development Gilead, pharma

Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the …

News
john-milligan-thumbnail-300x300

Gilead’s CEO and Chairman to both step down before year’s end

July 30, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …

Appointment
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra

With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …

News

Gilead’s CEO and Chairman to both step down before year’s end

July 26, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025